ROCK1 and obesity due to melanocortin 4 receptor deficiency: Nonspecific ROCK1 inhibitors fasudil and Y-27632 demonstrate inhibitor pharmacotherapy is beneficial for these diseases; however, adverse effects such as hypotension, insulin resistance, and obesity are observed when ROCK expression/activity is non-specifically altered or systemically downregulated (25, 32–35, 62, 63).